Your browser is no longer supported. Please, upgrade your browser.
ORMP Oramed Pharmaceuticals Inc. monthly Stock Chart
ORMP [NASD]
Oramed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own2.60% Shs Outstand14.76M Perf Week24.87%
Market Cap68.93M Forward P/E- EPS next Y-0.68 Insider Trans26.69% Shs Float14.31M Perf Month49.20%
Income-15.00M PEG- EPS next Q-0.25 Inst Own16.30% Short Float0.32% Perf Quarter56.19%
Sales2.60M P/S26.51 EPS this Y-8.60% Inst Trans-3.18% Short Ratio0.27 Perf Half Y38.99%
Book/sh1.23 P/B3.80 EPS next Y13.90% ROA-35.20% Target Price13.50 Perf Year10.14%
Cash/sh1.77 P/C2.64 EPS next 5Y- ROE-56.10% 52W Range2.32 - 5.80 Perf YTD55.67%
Dividend- P/FCF- EPS past 5Y-7.80% ROI-43.50% 52W High-19.48% Beta1.35
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin96.60% 52W Low101.57% ATR0.45
Employees13 Current Ratio5.10 Sales Q/Q16.70% Oper. Margin- RSI (14)65.33 Volatility19.03% 11.19%
OptionableYes Debt/Eq0.00 EPS Q/Q22.20% Profit Margin- Rel Volume3.25 Prev Close4.67
ShortableYes LT Debt/Eq0.00 EarningsDec 11 Payout- Avg Volume165.97K Price4.67
Recom1.50 SMA2043.87% SMA5046.55% SMA20039.37% Volume539,812 Change0.00%
Sep-11-19Initiated Ladenburg Thalmann Buy $7
Dec-11-17Resumed B. Riley FBR, Inc. Buy $20
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Nov-19-15Initiated FBR Capital Outperform $15
Apr-13-15Resumed MLV & Co Buy $27 → $30
Jan-30-14Reiterated Aegis Capital Buy $30 → $35
Jan-08-14Reiterated Aegis Capital Buy $25 → $30
Jan-08-14Initiated MLV & Co Buy $27
Dec-03-13Initiated Aegis Capital Buy $25
Dec-05-19 09:12AM  Oramed Appoints Dr. Arie Mayer to Board of Directors PR Newswire
Dec-02-19 09:16AM  Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Dropped 41% In The Last Three Years Simply Wall St. +29.71%
08:25AM  Oramed to Present a Scientific Poster at International Diabetes Federation Congress PR Newswire
Nov-25-19 09:57AM  Oramed working on first insulin pill for diabetes Yahoo Finance Video +10.94%
Nov-21-19 08:27AM  Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology PR Newswire +10.29%
Nov-19-19 08:55AM  Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire -7.12%
Nov-14-19 07:28AM  Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire
Nov-12-19 07:00AM  Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire -14.05%
Oct-21-19 03:06PM  How Does Investing In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Impact The Volatility Of Your Portfolio? Simply Wall St.
Sep-20-19 12:20PM  We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-18-19 08:38AM  Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire
Sep-17-19 08:40AM  Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire
Sep-03-19 08:25AM  Oramed to Present at Three Upcoming Conferences PR Newswire
Aug-16-19 08:31AM  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Insiders Increased Their Holdings Simply Wall St.
Aug-05-19 04:05PM  7 Stocks the Insiders Are Buying on Sale InvestorPlace
Jul-11-19 12:28PM  What Kind Of Investor Owns Most Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)? Simply Wall St.
Jul-10-19 08:40AM  Oramed to Present at World Diabetes Congress PR Newswire
Jul-02-19 08:25AM  Oramed Announces Xiaoming Gao Joins Board of Directors PR Newswire -8.09%
Jun-25-19 10:50AM  ORMP: Phase 2b Trial of ORMD-0801 Fully Enrolled; Data Expected 4Q19 Zacks Small Cap Research
Jun-18-19 08:40AM  Oramed Provides Clinical Update with Meaningful Data Expected by Year-End PR Newswire
Jun-03-19 09:25AM  Oramed to Present at BIO International Convention PR Newswire
May-21-19 08:55AM  Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801 PR Newswire
May-07-19 04:15PM  ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19 Zacks Small Cap Research
Apr-29-19 08:25AM  Oramed to Present at ThinkEquity Conference PR Newswire
Apr-28-19 09:47AM  Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Slid 60% In The Last Five Years Simply Wall St.
Apr-11-19 08:55AM  Oramed to Present at 3rd Annual Clinical Trials Summit PR Newswire
Apr-04-19 08:55AM  Oramed Patent Allowed in the U.S. for Oral Exenatide PR Newswire
Apr-03-19 08:55AM  Oramed to Present at H.C. Wainwright Global Life Sciences Conference PR Newswire
Mar-28-19 08:40AM  Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology PR Newswire +5.34%
Mar-26-19 08:40AM  Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules PR Newswire
Feb-06-19 02:31PM  Does The Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Price Tend To Follow The Market? Simply Wall St.
08:25AM  Oramed to Present at BIO CEO & Investor Conference PR Newswire
Jan-24-19 10:45AM  ORMP: Multiple Catalysts in 2019 Zacks Small Cap Research
Jan-22-19 08:25AM  Oramed Initiates Phase I Oral GLP-1 Study Under IND PR Newswire
Jan-15-19 08:55AM  Oramed Pharmaceuticals' CEO Letter to Shareholders PR Newswire
Jan-09-19 08:40AM  Oramed Receives Additional $3 Million Milestone Payment from HTIT PR Newswire
Dec-17-18 01:45PM  ORMP: Two Studies Ongoing for ORMD-0801 with Data Readouts in 2019 Zacks Small Cap Research
Nov-27-18 01:12PM  Is Oramed Pharmaceuticals Incs (NASDAQ:ORMP) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-15-18 11:45AM  ORMP: Transferring Coverage; Multiple Clinical Readouts for Oral Protein Delivery Technology Over Next 12-18 Months Zacks Small Cap Research
Nov-13-18 08:48AM  Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study PR Newswire
Nov-05-18 08:25AM  Oramed to Present at the Tides Europe 2018 Conference PR Newswire
Oct-23-18 08:25AM  Oramed to Present at Cardiometabolic Health Congress PR Newswire
Oct-04-18 08:25AM  Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH PR Newswire
Sep-20-18 02:23PM  Is Oramed Pharmaceuticals Incs (NASDAQ:ORMP) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Sep-17-18 10:35AM  Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule PR Newswire
Aug-28-18 08:25AM  Oramed to Present at the H.C. Wainwright Global Investment Conference PR Newswire
Jul-24-18 08:25AM  Oramed Granted Japanese Patent for GLP-1 Analog Capsule PR Newswire
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
Jul-12-18 06:36PM  Oramed: Fiscal 3Q Earnings Snapshot Associated Press
Jul-06-18 05:00PM  Oramed Announces Closing of $18.1 Million Registered Direct Offering PR Newswire
Jul-03-18 01:48AM  Oramed Announces $18.1 Million Registered Direct Offering PR Newswire -8.86%
Jun-25-18 08:25AM  Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin PR Newswire
Jun-21-18 08:25AM  Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801 PR Newswire
Jun-19-18 08:25AM  Oramed to be Added to Russell Microcap® Index PR Newswire
Jun-12-18 08:25AM  Oramed to Present at the American Diabetes Association 78th Scientific Sessions PR Newswire
May-30-18 08:25AM  Oramed Patent Allowed in the US for Oral Administration of Proteins PR Newswire +15.61%
May-10-18 09:39AM  For Diabetes Patients, Management Solutions Are As Critical As Medications Market Exclusive
May-07-18 08:25AM  Oramed to Present at Conferences in May PR Newswire
Apr-23-18 08:25AM  Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin PR Newswire
Mar-27-18 08:25AM  Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference PR Newswire
Mar-15-18 08:48AM  Oramed to Present at Oppenheimer's Annual Healthcare Conference PR Newswire
Feb-28-18 08:25AM  Oramed Adds Two New Members to its Scientific Advisory Board PR Newswire
Feb-20-18 08:25AM  Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension PR Newswire
Feb-06-18 08:25AM  Oramed to Present at BIO CEO Investor Conference PR Newswire
Jan-19-18 10:50AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018 Capital Cube
08:25AM  Oramed Pharmaceuticals' CEO Issues Letter to Shareholders PR Newswire
Jan-18-18 07:50AM  Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy ACCESSWIRE
Jan-12-18 12:25PM  Three Diabetes Clinical Trials to Watch in 2018 GuruFocus.com
05:01AM  Oramed reports 1Q loss Associated Press
Nov-14-17 08:00AM  Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule PR Newswire
Oct-31-17 08:35AM  Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins PR Newswire
Oct-24-17 09:25AM  Oramed to Present at the Diabetes Technology Meeting PR Newswire
Oct-17-17 08:40AM  Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists PR Newswire
Sep-25-17 08:55AM  Oramed to Present at the Disruptive Growth Showcase Conference PR Newswire
Sep-22-17 12:55PM  Oramed Now Has a Clear Path to Market With Oral Insulin GuruFocus.com
Sep-05-17 09:00AM  Oramed (ORMP): Successful Meeting with FDA for Oral Insulin Zacks Small Cap Research
06:00AM  Oramed Announces Successful Meeting with FDA for Oral Insulin PR Newswire
Aug-29-17 08:50AM  Oramed to Present at the Rodman & Renshaw Global Investment Conference PR Newswire
Aug-21-17 04:26PM  3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs GuruFocus.com
Jul-18-17 08:50AM  Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs PR Newswire
Jul-12-17 08:50AM  Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017 PR Newswire
Jul-11-17 08:50AM  Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program PR Newswire
Jul-10-17 10:57AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017 Capital Cube
Jul-06-17 07:16PM  Oramed reports 3Q loss Associated Press
Jul-05-17 08:50AM  Oramed Announces Dual-Listing on Tel Aviv Stock Exchange PR Newswire
Jun-27-17 08:45AM  Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule PR Newswire
Jun-12-17 08:17AM  Oramed Plans Secondary Listing in Tel Aviv Soon, CEO Kidron Says Bloomberg
Jun-06-17 08:45AM  Oramed to Present at the American Diabetes Association 77th Scientific Sessions PR Newswire
Jun-05-17 10:09AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-18-17 08:45AM  Oramed to Present at Conferences Next Week PR Newswire
May-09-17 08:45AM  Oramed Granted Canadian Patent for GLP-1 Analog Capsule PR Newswire
May-05-17 10:24AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 Capital Cube
May-02-17 01:00PM  Oramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule Zacks Small Cap Research
08:45AM  Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule PR Newswire
May-01-17 01:40PM  Oramed Gaining Strength in Oral Diabetes Market GuruFocus.com
Apr-20-17 08:30AM  Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule PR Newswire
Apr-06-17 05:01AM  Oramed reports 2Q loss Associated Press
Apr-04-17 08:45AM  Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists PR Newswire
Mar-22-17 08:45AM  Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017 PR Newswire
Mar-21-17 09:28AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sank LeonardDirectorSep 09Buy2.9225,00073,000374,999Sep 11 05:17 PM
Sank LeonardDirectorJul 18Buy3.864,49717,336349,999Jul 18 01:31 PM
Sank LeonardDirectorJul 17Buy3.6330,020109,059345,502Jul 18 01:31 PM
Sank LeonardDirectorJul 16Buy3.4720,00069,316315,482Jul 18 01:31 PM
Sank LeonardDirectorJul 11Buy3.221,3204,250295,482Jul 15 07:02 PM